Felis ISSN 2398-2950

Esmolol

Contributor(s): Mark Rishniw

Introduction

Name

  • Esmolol.

Class of drug

  • Ultra short-acting beta blocker.

Description

Chemical name

  • (+/-)-Methyl-p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate HCl.

Molecular formula

  • C16H26NO4.Cl.

Molecular weight

  • 331.8.

Physical properties

  • White crystalline powder.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Treatment of supraventricular tachycardia

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

Sympathomimetics

Anesthetic agents, phenothiazines, antihypertensives, diazepam, diuretics and antiarrhythmics

  • Enhance hypotensive effect.

Calcium channel blockers

  • Diltiazem   Diltiazem  and verapamil   Verapamil  increase risk of bradycardia, severe hypotension, heart failure and AV block.

Digoxin

  • May increase [digoxin] by 20%.
  • Bradycardia increased by concurrent administration.

Thyroid hormones

  • Enhance metabolism of esmolol thus reduce effect.
  • Dose of esmolol should be decreased when initiating methimazole   Carbimazole  therapy.

Cimetidine

  • May decrease metabolism of esmolol.

Muscle relaxants

  • Esmolol enhances effects of suxamethonium   Suxamethonium  , tubocurarine.

Phenobarbitone and phenytoin

  • May increase rate of metabolism of esmolol by hepatic enzyme induction.

Theophylline

  • May block bronchodilatory effects of theophylline   Theophylline  .

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Other sources of information

  • Based onSmall Animal Formulary. Tennant, Bryn (1999) 3rd edn. Cheltenham: BSAVA.

ADDED